Greater Cincinnati company teams with Kansas startup to steer approval of ADHD drugs

A Greater Cincinnati company has partnered with a Kansas pharmaceutical startup to help advance its development of two new ADHD treatments. Cingulate Therapeutics LLC, based in Kansas City, Kan., entered a service agreement with Blue Ash-based Camargo Pharmaceutical Services, which provides comprehensive drug development services, to help prepare the company’s submissions to the Food and Drug Administration. “We’re excited to h ave them as our partner on this,” Cingulate CEO Shane Schaffer…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news